Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
32828-81-2
Molecular formula
C21H20N4O3
Molecular weight
376.41 g/mol
Drug class
Antiplatelet agentthromboxane A2 receptor antagonist and thromboxane synthase inhibitor
Mechanism of action
Inhibits platelet aggregation through antagonism of thromboxane A2 receptors and inhibition of thromboxane A2 synthesis. Clinical pharmacology studies show reduced platelet aggregation and thromboxane-related activity, although the relative contribution of the two actions varies by experimental setting.
Indications / reported uses
Historically used for peripheral arterial disease and thrombotic vascular disorders in selected countries; current availability and authorisation are jurisdiction-specific.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Picotamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Picotamide Permitted Daily Exposure (PDE) report (the Picotamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Picotamide Occupational Exposure Limit (OEL) report (the Picotamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.